WVE files 8-K; press release for quarter ended September 30, 2025

Rhea-AI Filing Summary

Wave Life Sciences Ltd. filed an 8-K announcing financial results for the quarter ended September 30, 2025. The accompanying press release was furnished as Exhibit 99.1 and incorporated by reference.

The company states the Item 2.02 information is being furnished and not deemed filed under the Exchange Act. Wave’s ordinary shares trade on The Nasdaq Global Market under the symbol WVE.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

7 Straits View #12-00 false 0001631574 0001631574 2025-11-10 2025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, Wave Life Sciences Ltd. announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 is furnished and not filed:

Exhibit No.		Description
99.1		Press Release issued by Wave Life Sciences Ltd. dated November 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Kyle Moran
		Kyle Moran
		Chief Financial Officer

Date: November 10, 2025

FAQ

What did WVE disclose in this 8-K?

The company announced financial results for the quarter ended September 30, 2025 and furnished the related press release as Exhibit 99.1.

Is the information considered filed or furnished?

The Item 2.02 information is furnished and not deemed filed under the Exchange Act.

Which exhibit contains the press release for WVE?

Exhibit 99.1 contains the press release dated November 10, 2025.

What is Wave Life Sciences’ trading symbol and exchange?

Wave Life Sciences’ ordinary shares trade under WVE on The Nasdaq Global Market.

What period do the announced results cover for WVE?

They cover the quarter ended September 30, 2025.